SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
复制标题
DOI：
10.1016/s2214-109x(20)30544-1
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
ICMR Serosurveillance Group
中科院分区：
文献类型：
--
作者：
Murhekar MV;Bhatnagar T;Selvaraju S;Saravanakumar V;Thangaraj JWV;Shah N;Kumar MS;Rade K;Sabarinathan R;Asthana S;Balachandar R;Bangar SD;Bansal AK;Bhat J;Chopra V;Das D;Deb AK;Devi KR;Dwivedi GR;Khan SMS;Kumar CPG;Kumar MS;Laxmaiah A;Madhukar M;Mahapatra A;Mohanty SS;Rangaraju C;Turuk A;Baradwaj DK;Chahal AS;Debnath F;Haq I;Kalliath A;Kanungo S;Kshatri JS;Lakshmi GGJN;Mitra A;Nirmala AR;Prasad GV;Qurieshi MA;Sahay S;Sangwan RK;Sekar K;Shukla VK;Singh PK;Singh P;Singh R;Varma DS;Viramgami A;Panda S;Reddy DCS;Bhargava B;ICMR Serosurveillance Group
2020年5月至6月，印度在21个邦的18岁或以上成年人中进行了首次全国严重急性呼吸综合征冠状病毒2（SARS-CoV-2）血清调查，发现SARS-CoV-2 IgG抗体血清阳性率为0.73%（95%CI 0.34 - 1.13）。我们的目的是评估印度一般人群中最近的全国范围内的血清阳性率。我们在印度70个地区的700个村庄或病房中10岁或以上的个人中进行了第二次家庭血清调查，这些村庄或病房包括在第一次血清调查中。年龄小于10岁的个人和在调查时没有作出答复的家庭被排除在外。对参与者进行了访谈，以收集有关社会人口统计学、提示COVID-19的症状、实验室确诊的COVID-19病例暴露史以及COVID-19疾病史的信息。3-5从每名参与者中采集静脉血mL，并使用Abbott SARS-CoV-2 IgG检测试剂盒检测血样。在应用采样权重并调整聚类和检测特征后估计血清阳性率。我们从每个家庭中随机抽取一份成人血清样本，比较两次血清调查之间成人血清阳性率。在2020年8月18日至9月20日期间，我们招募并收集了来自15 613个家庭的29 082名个人的血清样本。 10岁及以上人群中SARS-CoV-2 IgG抗体的加权和校正血清阳性率为6.6%（95%CI 5.8 - 7.4）。在随机选择的15084名成年人（每个家庭一名）中，加权和调整后的血清阳性率为7.1%（6.2 - 8.2）。 不同年龄组、性别和职业的血清阳性率相似。城市贫民区的血清阳性率最高，其次是城市非贫民区和农村地区。我们估计，截至2020年8月18日，该国累计有7430万例感染，每报告一例COVID-19病例就有26-32例感染。到2020年8月18日，印度10岁或以上的15人中约有一人感染了SARS-CoV-2。2020年5月至8月期间，成人血清阳性率增加了约10倍。8月份的感染病例比低于5月份，反映出全国各地的检测大幅增加。印度医学研究理事会。
The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May–June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34–1·13). We aimed to assess the more recent nationwide seroprevalence in the general population in India. We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey. Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded. Participants were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. 3–5 mL of venous blood was collected from each participant and blood samples were tested using the Abbott SARS-CoV-2 IgG assay. Seroprevalence was estimated after applying the sampling weights and adjusting for clustering and assay characteristics. We randomly selected one adult serum sample from each household to compare the seroprevalence among adults between the two serosurveys. Between Aug 18 and Sept 20, 2020, we enrolled and collected serum samples from 29 082 individuals from 15 613 households. The weighted and adjusted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6·6% (95% CI 5·8–7·4). Among 15 084 randomly selected adults (one per household), the weighted and adjusted seroprevalence was 7·1% (6·2–8·2). Seroprevalence was similar across age groups, sexes, and occupations. Seroprevalence was highest in urban slum areas followed by urban non-slum and rural areas. We estimated a cumulative 74·3 million infections in the country by Aug 18, 2020, with 26–32 infections for every reported COVID-19 case. Approximately one in 15 individuals aged 10 years or older in India had SARS-CoV-2 infection by Aug 18, 2020. The adult seroprevalence increased approximately tenfold between May and August, 2020. Lower infection-to-case ratio in August than in May reflects a substantial increase in testing across the country. Indian Council of Medical Research.